The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.
Targeting macrophages: therapeutic approaches in cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–233 of 233
Marra, M., Salzano, G., Leonetti, C., Tassone, P., Scarsella, M., Zappavigna, S., Calimeri, T., Franco, R., Liguori, G., Cigliana, G., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.03.004 · Cited by 104
Nowak, A. K., Cook, A., McDonnell, A. M., Millward, M., Creaney, J., Francis, R. J., Hasani, A., Segal, A., Musk, A. W., Turlach, B. A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv387 · Cited by 104
Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor
Mantovani, A., Ming, W. J., Balotta, C., Benomar, A., & Bottazzi, B. (1986) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(86)90013-2 · Cited by 102
Zhang, X., Chen, Y., Hao, L., Hou, A., Chen, X., Li, Y., Wang, R., Luo, P., Ruan, Z., Ou, J., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.004 · Cited by 99
Tang, R., Ojeda‐Uribe, M., Pouillart, P., Scholl, S., Beuvon, F., & Mosseri, V. (1992) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240500403 · Cited by 98
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, É., Park, Y. C., Parekh, T. V., & Poveda, A. M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.001 · Cited by 95
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment
Peña, C. G., Nakada, Y., Saatcioglu, H. D., Aloisio, G. M., Cuevas, I., Zhang, S., Miller, D. S., Lea, J. S., Wong, K., DeBerardinis, R. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82152 · Cited by 94
Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions
Morandi, F., & Pistoia, V. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00394 · Cited by 94
Liguori, M., Buracchi, C., Pasqualini, F., Bergomas, F., Pesce, S., Sironi, M., Grizzi, F., Mantovani, A., Belgiovine, C., & Allavena, P. (2016) · Oncotarget · doi:10.18632/oncotarget.9340 · Cited by 94
Colorectal Cancer: Looking for Answers in the Microbiota
Jobin, C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0042 · Cited by 92
Marra, M., Salzano, G., Leonetti, C., et al. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.06.018 · Cited by 91
Guo, B., Cen, H., Tan, X., & Ke, Q. (2016) · BMC Medicine · doi:10.1186/s12916-016-0711-6 · Cited by 91
Therapeutic applications of TRAIL receptor agonists in cancer and beyond
Amarante-Mendes, G. P., & Griffith, T. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.09.001 · Cited by 89
Anti-CD40 agonist antibodies: Preclinical and clinical experience
Khalil, M., & Vonderheide, R. H. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.06.001 · Cited by 81
Modes of Action of TLR7 Agonists in Cancer Therapy
Kobold, S., Wiedemann, G. M., Rothenfußer, S., & Endres, S. (2014) · Immunotherapy · doi:10.2217/imt.14.75 · Cited by 76
Trial Watch: Immunotherapy plus radiation therapy for oncological indications
Vacchelli, E., Bloy, N., Aranda, F., Buqué, A., Cremer, I., Demaria, S., Eggermont, A. M. M., Formenti, S. C., Fridman, W. H., Fucikova, J. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214790 · Cited by 76
Smith, H. O., Anderson, P., Kuo, D. Y., Goldberg, G. L., DeVictoria, C. L., Boocock, C. A., Jones, J. G., Runowicz, C. D., Stanley, E. R., & Pollard, J. W. (1995) · PubMed · Cited by 75
Self-citationSmith, D. A. B., Conkling, P., Richards, D., Nemunaitis, J. J., Boyd, T. E., Mita, A. C., Bourdonnaye, G. D. L., Wages, D. S., & Bexon, A. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1547-6 · Cited by 75
Tumor immune microenvironment characterization and response to anti-PD-1 therapy.
Santarpía, M., & Karachaliou, N. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0022 · Cited by 73
Comito, G., Segura, C. P., Taddei, M. L., Lanciotti, M., Serni, S., Morandi, A., Chiarugi, P., & Giannoni, E. (2016) · Oncotarget · doi:10.18632/oncotarget.9497 · Cited by 64
Entenberg, D. R., Rodríguez-Tirado, C., Kato, Y., Kitamura, T., Pollard, J. W., & Condeelis, J. S. (2015) · IntraVital · doi:10.1080/21659087.2015.1086613 · Cited by 63
Self-citationImproving cancer immunotherapy by targeting the STATe of MDSCs
de Haas, N., de Koning, C. C. H., Spilgies, L. M., de Vries, I. J. M., & Hato, S. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196312 · Cited by 63
The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma
Smith, H. O., Stephens, N. D., Qualls, C., Fligelman, T., Wang, T., Lin, C., Burton, E. M., Griffith, J. K., & Pollard, J. W. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.002 · Cited by 60
Self-citationTumor immune microenvironment characterization and response to anti-PD-1 therapy
Mariacarmela, Santarpia, Niki, & Karachaliou (2015) · 癌症生物学与医学:英文版 · Cited by 58
Ben‐Aharon, I., Vidal, L., Rizel, S., Yerushalmi, R., Shpilberg, O., Sulkes, A., & Stemmer, S. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070044 · Cited by 47
Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race
Harrer, D. C., Dörrie, J., & Schaft, N. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.236 · Cited by 42
Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme
Hirano, H., Tanioka, K., Yokoyama, S., Akiyama, S., & Kuratsu, J. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.95.1.0089 · Cited by 32
Marra, M., Abbruzzese, A., Addeo, R., Prete, S., Tassone, P., Tonini, G., Tagliaferri, P., Santini, D., & Caraglia, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789760285 · Cited by 32
Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft‐tissue sarcoma
Guth, A., Hafeman, S., Elmslie, R. E., & DOW, S. W. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00319.x · Cited by 30
Synovial colony-stimulating factor-1 mRNA expression in diffuse pigmented villonodular synovitis.
Molena, B., Sfriso, P., Oliviero, F., Pagnin, E., Teramo, A., Lunardi, F., Stramare, R., Scanu, A., Nardacchione, R., Rubaltelli, L., et al. (2011) · PubMed · Cited by 20
Scholl, S., Mosseri, V., Tang, R., et al. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb17199.x · Cited by 17
A multi-targeted approach to treating bone metastases
Camacho, D. F., & Pienta, K. J. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9476-y · Cited by 16
Anti-CCL2: building a reservoir or opening the floodgates to metastasis?
Hitchcock, J. R., & Watson, C. J. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0573-4 · Cited by 14
Cited by
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Macrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,229
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Tumor-Associated Macrophages in Tumor Immunity
Pan, Y., Yu, Y., Wang, X., & Zhang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583084 · Cited by 1,872
Metadata
- Authors
- Cassetta, L., & Pollard, J. W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-10-26
- Volume
- 17
- Issue
- 12
- Pages
- 887-904
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2898415660
- Cited by
- 2,048
- References
- 233
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.